spinal cord injury stem cell treatment

Early, but encouraging data from Asterias on stem cells for spinal cord injury

Asterias

As I posted recently, Asterias Biotherapeutics has had good early safety results so far in its historic stem cell trial for spinal cord injury and now the company presented some early, encouraging hints at efficacy.  However, a caveat here is that this is not an RCT (randomized controlled trial). Ed Wirth, CMO of Asterias, presented the …

Early, but encouraging data from Asterias on stem cells for spinal cord injury Read More »

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial

jane-lebkowski

The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung …

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »